Clinical Trial Update: Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-doses of inhaled melphalan for COVID-19 pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Pneumonia

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: Federal State Budgetary Institution, Pulmonology Scientific Research Institute | Conditions: COVID-19, Viral Pneumonia | Phase 2 | Status: UNKNOWN